Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684143 | 1.00 | CA2 (0.56) | CA2CNR1KDM4EAKR1B1HSD17B10 | |
| SCHEMBL31561597 | 0.86 | CA2 (0.62) | CA2CNR1KDM4EAKR1B1HSD17B10 | |
| SCHEMBL3237494 | 0.86 | CA2 (0.62) | CA2CNR1KDM4EAKR1B1HSD17B10 | |
| SCHEMBL4862702 | 0.84 | CA2 (0.56) | CA2CNR1AKR1B1MAPTCA12 | |
| SCHEMBL8960439 | 0.84 | CA2 (0.56) | CA2CNR1KDM4EAKR1B1HSD17B10 | |
| SCHEMBL13542579 | 0.83 | CA2 (0.51) | CA2CNR1KDM4EAKR1B1HSD17B10 | |
| SCHEMBL8120975 | 0.83 | KDM4E (0.49) | CA2CNR1KDM4ERXFP1PDGFRB | |
| SCHEMBL28568569 | 0.82 | CA2 (0.71) | CA2CNR1KDM4EAKR1B1HSD17B10 | |
| SCHEMBL29520525 | 0.82 | CA2 (0.57) | CA2CNR1AKR1B1CA12CA1 | |
| SCHEMBL14502491 | 0.81 | CA2 (0.53) | CA2CNR1KDM4EAKR1B1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081778-A | Central chiral sulfonyl indole and synthesis method thereof | 南京理工大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-112409236-B | Method for synthesizing 3-thioether indole with high selectivity | 上海应用技术大学 | 2022-10-14 | — | — | CN | disclosed |
| CN-108129440-B | Method for synthesizing chiral chromene derivative | 中国科学院大连化学物理研究所 | 2021-05-28 | — | — | CN | disclosed |
| CN-112409236-A | Method for synthesizing 3-thioether indole with high selectivity | 上海应用技术大学 | 2021-02-26 | — | — | CN | disclosed |
| CN-109438317-A | A kind of preparation method of nitrogen-alkyl (deuteroalkyl) heteroaromatic and alkyl (deuteroalkyl) aryl ethers compounds | 武汉大学 | 2019-03-08 | — | — | CN | disclosed |
| CN-106366032-A | Applications of chiral organic alkali in preparation of chiral sulfur-containing indole compound in water-oil two-phase system | 中国科学院大连化学物理研究所 | 2017-02-01 | — | — | CN | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2606032-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | University Of Washington Through Its Center For Commercialization (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| CN-1706802-A | Prepn process of 2-ary lactate, naprosyn and ibuprofen | SHANHAI INST OF ORGANIC CHEMIS (CN) | 2005-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | CA2 1599/4885CNR1 2351/4885KDM4E 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.